FLOMICS BIOTECH IS WRITING THE NEXT CHAPTER IN PRECISION DIAGNOSTICS
After joining the GSA Alumni network, Flomics Biotech continues to demonstrate how innovation in healthtech can evolve beyond the global stage. As the demand for early and accurate cancer detection intensifies worldwide, the Barcelona based startup is reinforcing its position at the forefront of precision diagnostics through continued scientific progress and strategic collaboration.
EXPANDING THE FRONTIERS OF MULTI-CANCER DETECTION
In January 2026, Flomics Biotech announced the launch of the BIOTEM project, a significant step forward in validating its liquid biopsy technology across seven different types of cancer. This initiative marks a crucial expansion of the company’s capabilities, moving beyond single-disease applications toward scalable, multi-cancer early detection.
By leveraging advanced RNA analysis from blood samples, Flomics aims to enable non-invasive, accessible, and highly accurate diagnostic solutions. The BIOTEM project reflects a broader industry shift toward early detection as a cornerstone of modern healthcare. In this context, Flomics is positioning itself not only as a technology provider, but as a key contributor to the future of preventive medicine.
STRENGTHENING EUROPEAN COLLABORATION THROUGH LIQUIDX
The launch of BIOTEM builds upon Flomics’ ongoing involvement in the European LiquiDx project, which reached an advanced stage of development in October 2025. This initiative brings together a wide network of public institutions, research centers, and private companies to accelerate the development of RNA-based liquid biopsy solutions for multiple cancer types.
Flomics’ role within LiquiDx highlights its growing importance within Europe’s biotech innovation landscape. By contributing its proprietary technology to a collaborative framework, the company is helping to bridge the gap between research and real-world clinical application. The project underscores the increasing importance of cross-sector partnerships in tackling complex global health challenges, where no single player can drive transformation alone.
A CONTINUING JOURNEY WITHIN THE GSA ALUMNI NETWORK
As part of the Global Startup Awards alumni network, Flomics Biotech exemplifies how recognition can translate into sustained impact. Its ongoing work in liquid biopsy and early detection not only reinforces its position within the global healthtech sector but also highlights the strength of a network where innovation continues to grow beyond the awards stage. In doing so, Flomics stands as a clear example of how GSA alumni are shaping the future of industries that matter most.
ABOUT THE GLOBAL STARTUP AWARDS
The Global Startup Awards discovers, supports, and celebrates visionary entrepreneurs and high-growth startups worldwide. Through competitions, community features, and storytelling, GSA helps founders connect, share insights, and accelerate their ventures.
Stay tuned for more inspiring stories from the GSA alumni network. There’s much more innovation ahead.